Increased viability of PC12 cells exposed to amyloid-beta peptide by transduction with human TAT-methionine sulfoxide reductase
- Authors
- Jung, B; Lee, EH; Chung, WS; Lee, SJ; Shin, SH; Joo, SH; Kim, SK; Lee, JH
- Issue Date
- Dec-2003
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Keywords
- Alzheimer's disease; amyloid-beta; methionine sulfoxide reductase; MsrA transduction; TAT-MsrA
- Citation
- NEUROREPORT, v.14, no.18, pp 2349 - 2353
- Pages
- 5
- Journal Title
- NEUROREPORT
- Volume
- 14
- Number
- 18
- Start Page
- 2349
- End Page
- 2353
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/24909
- DOI
- 10.1097/01.wnr.0000094489.16884.43
- ISSN
- 0959-4965
1473-558X
- Abstract
- Methionine sulfoxide reductase (MsrA) catalyzes the reduction of methionine sulfoxide to methionine, which is able to scavenge oxidatively damaged proteins. Oxidative stress has been linked to the pathophysiology of Alzheimer's disease, and a decrease in MsrA activity has also been implicated in Alzheimer's disease. The transactivator of transcription (TAT) protein from human immunodeficiency virus I has been used to deliver full-length proteins into mammalian cells. We produced genetic in-frame TAT-MsrA fusion protein and successfully transduced it into PCl2 cells, where it showed enzymatic activity. We showed that transduction of TAT-MsrA increased cell viability and reduced DNA fragmentation in PCl2 cells treated with amyloid-beta (Abeta). We suggest that MsrA transduction could reduce the oxidative damage caused to cellular proteins by Abeta and could play a role in the treatment of Alzheimer's disease. (C) 2003 Lippincott Williams Wilkins.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Natural Sciences > Department of Life Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.